|Awarded On||August 21, 2019|
|Title||Development of an antibody targeting PCDH7 for lung cancer therapy|
|Award Mechanism||Bridging the Gap: Early Translational Research Awards|
|Institution/Organization||The University of Texas Southwestern Medical Center|
|Principal Investigator/Program Director||Kathryn O'Donnell|
|Cancer Sites||Breast, Lung and Bronchus, Melanoma|
*Pending contract negotiation
Lung cancer is the leading cause of cancer deaths worldwide and is caused by mutations in DNA that promote uncontrolled cell growth or inappropriate cell survival. Patients have few therapeutic options, and disease progression is inevitable, underscoring the critical need for the identification of new therapeutic approaches to treat this disease. Our laboratory is one of the first to investigate the role of the cell surface protein PROTOCADHERIN 7 (PCDH7) in lung cancer development. PCDH7 represents an attractive target for treating lung cancer for several reasons. PCDH7 is present at higher levels in lung cancer cells compared to normal lung epithelial cells and high PCDH7 levels correl...